Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.

about

Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.

Item

http://www.wikidata.org/entity/Q40583931

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Adjuvant Chemotherapy and Tras ...... ive Early-Stage Breast Cancer.

@en

type

Item

label

Adjuvant Chemotherapy and Tras ...... ive Early-Stage Breast Cancer.

@en

prefLabel

Adjuvant Chemotherapy and Tras ...... ive Early-Stage Breast Cancer.

@en

P1476

Adjuvant Chemotherapy and Tras ...... ive Early-Stage Breast Cancer.

@en

P2093

Clifford A Hudis

http://www.w3.org/2001/XMLSchema#string

Elizabeth P Cowell

http://www.w3.org/2001/XMLSchema#string

Heather L McArthur

http://www.w3.org/2001/XMLSchema#string

Karen A Cadoo

http://www.w3.org/2001/XMLSchema#string

Patrick G Morris

http://www.w3.org/2001/XMLSchema#string

Sujata Patil

http://www.w3.org/2001/XMLSchema#string

P2860

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration

Trastuzumab containing regimens for early breast cancer

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.

P304

487-493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLBC.2016.07.013

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27622751

http://www.w3.org/2001/XMLSchema#string

P932

5575753

http://www.w3.org/2001/XMLSchema#string